Pearson Mark E. 4
4 · SOLIGENIX, INC. · Filed Jul 10, 2019
Insider Transaction Report
Form 4
SOLIGENIX, INC.SNGX
Pearson Mark E.
Director10% Owner
Transactions
- Award
Common Stock
2019-06-28$0.71/sh+78,338$55,620→ 78,338 total(indirect: See footnote)
Holdings
- 2,500,000
Common Stock
Footnotes (2)
- [F1]These securities were issued in lieu of cash compensation payable for services rendered, with the number of shares issued being calculated based upon the closing price of $0.71 on June 28, 2019. The transaction is exempt under Rule 16b-3 of the Securities Exchange Act of 1934.
- [F2]These securities are held by Altamont Pharmaceutical Holdings, LLC, a company for which the reporting person serves as general partner and chief executive officer. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or any other purpose.